Skip to main content
  • COAPT shows MitraClip plus medical therapy has better outcomes in HF patients with secondary MR than medical therapy alone

    SAN DIEGO — MitraClip plus maximally-tolerated guideline-directed medical therapy (GDMT) proved to be a significantly more effective treatment for patients with heart failure (HF) and moderate to severe secondary mitral regurgitation (MR) compared to GDMT alone, according to results of the highly anticipated COAPT trial released Sunday at the Transcatheter Cardiovascular Therapeutics (TCT) conference.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details